Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rumin Zhang

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 17, 2013
Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitorYongqi Deng, Gerald W Shipps, Lianyun Zhao, et al.
Nature Communications|January 2, 2025
Targeting chromosomally unstable tumors with a selective KIF18A inhibitorAaron F Phillips, Rumin Zhang, Mia Jaffe, et al.
Therapeutics and Clinical Risk Management|January 14, 2021
Clinical Features for Severely and Critically Ill Patients with COVID-19 in Shandong: A Retrospective Cohort StudyShengyu Zhou, Jiawei Xu, Wenqing Sun, et al.
Journal of Medicinal Chemistry|March 29, 2022
Lead Optimization to Advance Protease-Activated Receptor-1 Antagonists in Early DiscoveryMihirbaran Mandal, Maria Madeira, Rupesh P Amin, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2024
Discovery of sulfone containing metallo-β-lactamase inhibitors with reduced bacterial cell efflux and histamine release issuesFrank Bennett, Yuhua Huang, Shuzhi Dong, et al.
Bioorganic & Medicinal Chemistry Letters|March 3, 2015
Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitorsBrian A McKittrick, John P Caldwell, Thomas Bara, et al.
Journal of Medicinal Chemistry|April 21, 2007
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimizationAndrew J Prongay, Zhuyan Guo, Nanhua Yao, et al.
Journal of Synchrotron Radiation|April 19, 2008
Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034Vincent Madison, Andrew J Prongay, Zhuyan Guo, et al.
Nature|September 30, 2015
Selective small-molecule inhibition of an RNA structural elementJohn A Howe, Hao Wang, Thierry O Fischmann, et al.
Cancer Discovery|April 26, 2013
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitorsErick J Morris, Sharda Jha, Clifford R Restaino, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Bioorganic & Medicinal Chemistry Letters|December 17, 2013
Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitorYongqi Deng, Gerald W Shipps, Lianyun Zhao, et al.
Nature Communications|January 2, 2025
Targeting chromosomally unstable tumors with a selective KIF18A inhibitorAaron F Phillips, Rumin Zhang, Mia Jaffe, et al.
Therapeutics and Clinical Risk Management|January 14, 2021
Clinical Features for Severely and Critically Ill Patients with COVID-19 in Shandong: A Retrospective Cohort StudyShengyu Zhou, Jiawei Xu, Wenqing Sun, et al.
Journal of Medicinal Chemistry|March 29, 2022
Lead Optimization to Advance Protease-Activated Receptor-1 Antagonists in Early DiscoveryMihirbaran Mandal, Maria Madeira, Rupesh P Amin, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2024
Discovery of sulfone containing metallo-β-lactamase inhibitors with reduced bacterial cell efflux and histamine release issuesFrank Bennett, Yuhua Huang, Shuzhi Dong, et al.
Bioorganic & Medicinal Chemistry Letters|March 3, 2015
Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitorsBrian A McKittrick, John P Caldwell, Thomas Bara, et al.
Journal of Medicinal Chemistry|April 21, 2007
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimizationAndrew J Prongay, Zhuyan Guo, Nanhua Yao, et al.
Journal of Synchrotron Radiation|April 19, 2008
Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034Vincent Madison, Andrew J Prongay, Zhuyan Guo, et al.
Nature|September 30, 2015
Selective small-molecule inhibition of an RNA structural elementJohn A Howe, Hao Wang, Thierry O Fischmann, et al.
Cancer Discovery|April 26, 2013
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitorsErick J Morris, Sharda Jha, Clifford R Restaino, et al.
Pageof 8